Stock listing

gettex:9PT Pliant Therapeutics, Inc. Aktie

German listing (gettex) of Pliant Therapeutics, Inc. · home listing NASDAQ:PLRX

Follow Pliant Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:PLRX

$0.595 USD -0.066 (-10.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:PLRX

Past year -61.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.572 – $0.614 USDNov 20, 2026
Volume
933,400 sharesNov 20, 2026
Market cap
$36.89M USDAt the close on Nov 20, 2026 · price × 61.99M shares outstanding
52-week range
$0.572 – $1.670 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$386,066 USDMedian day 326,684 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Pliant Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PLRX · Home$0.595 USD-0.066 (-10.0%)933,400$0.600$0.614$0.572$0.661Close on Nov 20, 2026
Frankfurt:9PT€0.531 EUR-0.052 (-9.0%)—€0.548€0.548€0.531€0.583Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PLRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.595-0.066-10.0%$0.600$0.614$0.572933,400
$0.661+0.001+0.1%$0.655$0.674$0.638939,630
$0.660-0.033-4.8%$0.697$0.712$0.651787,559
$0.693-0.004-0.5%$0.696$0.710$0.660999,035
$0.697-0.043-5.8%$0.740$0.754$0.690876,379
$0.740-0.038-4.8%$0.775$0.775$0.733525,308
$0.778-0.008-1.0%$0.786$0.786$0.760270,142
$0.786-0.014-1.7%$0.820$0.820$0.770360,585
$0.800-0.010-1.2%$0.806$0.837$0.790288,543
$0.810-0.006-0.7%$0.809$0.824$0.801151,613
$0.816-0.036-4.2%$0.850$0.850$0.795340,323
$0.852-0.009-1.0%$0.860$0.882$0.842205,287
$0.861+0.022+2.6%$0.835$0.864$0.835146,338
$0.839-0.020-2.3%$0.850$0.855$0.839385,679
$0.859-0.001-0.1%$0.856$0.883$0.840169,524
$0.860-0.030-3.3%$0.875$0.903$0.851205,951
$0.890+0.033+3.8%$0.857$0.890$0.845118,076
$0.857+0.007+0.9%$0.842$0.882$0.830346,675
$0.850-0.014-1.6%$0.867$0.899$0.837298,915
$0.864-0.002-0.2%$0.870$0.879$0.831446,817
$0.865-0.021-2.3%$0.900$0.900$0.851289,803
$0.886-0.027-2.9%$0.927$0.928$0.880340,621
$0.912+0.014+1.5%$0.903$0.940$0.896319,686
$0.899-0.001-0.1%$0.913$0.928$0.875292,201
$0.900-0.073-7.5%$0.970$0.985$0.890582,722
$0.972+0.089+10.0%$0.900$0.972$0.900481,347
$0.884-0.084-8.7%$0.961$0.977$0.884988,883
$0.968-0.018-1.8%$0.983$0.998$0.961284,640
$0.986-0.034-3.3%$1.030$1.030$0.986272,193
$1.020+0.020+2.0%$0.990$1.030$0.986288,527
$1.000+0.010+1.0%$1.000$1.034$0.981568,045
$0.990-0.040-3.9%$1.030$1.030$0.970756,501
$1.0300.0000.0%$1.040$1.040$1.010276,386
$1.030-0.005-0.5%$1.040$1.054$1.020295,615
$1.035-0.015-1.4%$1.060$1.065$1.030402,811
$1.050-0.030-2.8%$1.100$1.100$1.050379,553
$1.0800.0000.0%$1.090$1.090$1.070238,681
$1.0800.0000.0%$1.090$1.120$1.080214,498
$1.0800.0000.0%$1.080$1.100$1.071349,131
$1.080-0.060-5.3%$1.140$1.140$1.080450,185
$1.140+0.015+1.3%$1.130$1.150$1.110398,028
$1.125-0.015-1.3%$1.140$1.140$1.100254,281
$1.140+0.030+2.7%$1.120$1.150$1.110326,684
$1.1100.0000.0%$1.120$1.130$1.110149,288
$1.110-0.020-1.8%$1.130$1.130$1.090438,690
$1.130+0.060+5.6%$1.090$1.140$1.090308,086
$1.070-0.050-4.5%$1.120$1.170$1.070983,068
$1.120-0.030-2.6%$1.150$1.155$1.110502,028
$1.150-0.020-1.7%$1.160$1.180$1.150208,878
$1.170+0.040+3.5%$1.140$1.180$1.140173,460
$1.130-0.020-1.7%$1.130$1.160$1.130299,397
$1.150+0.015+1.3%$1.120$1.170$1.120450,171
$1.135-0.025-2.2%$1.110$1.175$1.110682,891
$1.160+0.030+2.7%$1.120$1.185$1.110559,895
$1.130-0.030-2.6%$1.150$1.170$1.130299,287
$1.160+0.050+4.5%$1.110$1.170$1.110740,063
$1.110+0.010+0.9%$1.110$1.128$1.100267,479
$1.100-0.010-0.9%$1.100$1.120$1.093400,005
$1.110-0.040-3.5%$1.150$1.150$1.110233,141
$1.150-0.010-0.9%$1.160$1.160$1.140112,828
$1.160-0.030-2.5%$1.190$1.190$1.150135,090
$1.190+0.050+4.4%$1.140$1.200$1.130321,952
$1.140-0.015-1.3%$1.140$1.150$1.120316,089
$1.155+0.035+3.1%$1.120$1.170$1.120504,685
$1.120-0.050-4.3%$1.188$1.188$1.120401,768
Ticker
gettex:9PT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Latest news

All Pliant Therapeutics, Inc. news

Pliant Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 119 in all · newest Nov 12, 2026 · oldest 2020
Decks
9 decks · latest September 2026

Where Pliant Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:PLRX · Home listingNASDAQUnited StatesUSD
LS Exchange:A2P4YVLS ExchangeGermanyEUR
Lang & Schwarz:A2P4YVLang & SchwarzGermanyEUR
BOATS:PLRXBOATSUnited StatesUSD
gettex:9PT · This pagegettexGermanyEUR
Dusseldorf:9PTDusseldorfGermanyEUR
Frankfurt:9PTFrankfurtGermanyEUR
Munich:9PTMunichGermanyEUR
Stuttgart:9PTStuttgartGermanyEUR
Tradegate:9PTTradegateGermanyEUR

Valuation

Price/book 0.3× against a median of 2.4×: the lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$104.2M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.06

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Pliant Therapeutics, Inc. · NASDAQ:PLRXUS$36.89M−US$104.2Mn/an/an/a0.3×n/a0.0×1.06
OSE Immunotherapeutics SA · EURONEXT:OSEUS$38.31MUS$52.28Mn/a18.2×n/a1.3×n/a1.3×n/a
KoBioLabs, Inc. · KRX:348150US$38.23MUS$6.96Mn/a0.1×n/a1.8×−6.4%0.2×n/a
Sprint Bioscience AB · OMXSTO:SPRINTUS$38.02MUS$28.89M5.1×2.1×3.7×4.3×54.4%0.0×n/a
Theralase Technologies Inc. · TSXV:TLTUS$37.89MUS$34.22Mn/a61.1×n/a7.9×−472.5%0.0×0.75
Connect Biopharma Holdings Limited · NASDAQ:CNTBUS$37.15MUS$18.16Mn/a4.9×n/a3.1×n/a0.0×0.93
Coiled Therapeutics PLC · LSE:COILUS$37.13MUS$30.46Mn/an/an/a0.6×n/a0.0×n/a
TaiRx, Inc. · TPEX:6580US$37.07MUS$28.61Mn/a33.8×n/a3.3×−793.3%0.0×n/a
Arovella Therapeutics Limited · ASX:ALAUS$36.01MUS$26.51Mn/an/an/a3.8×n/a0.0×n/a
Grace Therapeutics, Inc. · NASDAQ:GRCEUS$35.97MUS$14.66Mn/an/an/a0.7×n/a0.0×0.77
Cantargia AB · OMXSTO:CANTAUS$35.59MUS$13.85M2.2×0.5×0.9×1.4×52.8%0.0×n/a
Median of the othersUS$37.14MUS$27.56M3.6×4.9×2.3×2.4×−6.4%0.0×0.77

Forecasts

3 hold · 1 sell · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
2.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.44 · 3 analysts

Team and board

Officers

OfficerRole
Craig BlanchetteSenior Vice President, Research
David RabenChief Medical Officer

Board

DirectorRole
Hoyoung HuhChairman
Bernard CoulieDirector
Darren ClineBoard Member
Flavia BorelliniDirector
Gayle CrowellBoard Member
John CurnutteBoard Member
Robert IannoneDirector
Steve KrognesMember
Thomas McCourtBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−5.8%
Q2 2026Aug 11, 2026 · After close+3.9%
Q1 2026May 11, 2026 · After close−1.7%
Q4 2025Mar 3, 2026+1.6%
Q3 2025Nov 6, 2025 · After close+4.6%
Q2 2025Aug 7, 2025 · After close−1.2%
Q1 2025May 8, 2025 · After close−3.4%
Q4 2024Feb 25, 2025 · Before open+4.6%
Q3 2024Nov 7, 2024 · After close−1.3%
Q2 2024Aug 7, 2024 · After close−2.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 6, 2024 · After close0.0%
Q4 2023Feb 27, 2024 · After close−3.4%
Q3 2023Nov 9, 2023 · After close−2.6%
Q2 2023Aug 9, 2023 · After close+3.3%
Q1 2023May 9, 2023 · After close+2.3%
Q4 2022Mar 9, 2023 · After close−2.1%
Q3 2022Nov 8, 2022 · After close−5.0%
Q2 2022Aug 8, 2022 · After close+11.2%
Q1 2022May 9, 2022 · After close+4.7%
Q4 2021Feb 28, 2022 · After close+11.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck24 slidesSeptember 2026
Technical Presentation (May 2025)Technical13 slidesMay 2025
ERS Congress 2024Conference13 slidesSeptember 2024
ERS Congress 2024Conference10 slidesSeptember 2024
AASLD: The Liver Meeting 2023Conference18 slidesNovember 2023
ERS International Congress 2023Conference18 slidesSep 10, 2023
Investor Presentation (January 2023)Investor deck70 slidesJan 9, 2023
2022 New Directions in Biology and Disease of Skeletal Muscle ConferenceConference25 slidesNovember 2022
Investor Presentation (January 2022)Investor deck29 slidesJan 10, 2022

Open Decks

IPO

Priced at US$16.00 a share on Jun 2, 2020.

Price
US$16.00 a share
Shares offered
9,000,000 shares of common stock
Offering size
US$144 million
Underwriters' option
Up to 1,350,000 more shares
Underwriters
Citigroup, Cowen, Piper Sandler, Needham & Company · In the order on the cover
Shares delivered
On or about Jun 5, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceMay 10, 2019
Filed publiclyMay 11, 2020
Amended twiceNewest Jun 2, 2020
Shares registered with an exchangeMay 29, 2020
Declared effective by the SECJun 2, 2020
Final prospectus, with the priceJun 3, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Jun 3, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue001.58M9.69M7.57M41.8M57.1M0
Cost of revenue1.70M2.13M1.84M3.68M3.20M666.0K
Gross profit-1.70M-2.13M1.58M9.69M7.57M41.8M57.1M-666.0K
Research and development109.2M169.3M127.8M96.9M77.5M66.2M47.4M24.4M14.5M
Selling, general and administrative47.2M59.1M57.9M39.9M27.6M17.3M10.9M6.50M3.82M
Operating income-156.4M-228.4M-184.1M-127.2M-97.5M-41.6M-1.23M-30.9M-18.3M
Depreciation and amortization1.70M2.13M1.84M1.82M1.53M1.31M1.11M666.0K292.0K
EBITDA-154.7M-226.2M-182.3M-125.4M-96.0M-40.3M-118.0K-30.2M-18.1M
Interest expense2.56M3.02M1.27M791.0K0366.0K216.0K00
Income before tax-149.3M-210.3M-161.3M-123.3M-97.3M41.5M600.0K-30.3M-18.3M
Income tax0000000639.0K2.29M
Net income-149.3M-210.3M-161.3M-123.3M-97.3M-41.5M-631.0K-30.3M-20.6M
Earnings per share, basic-2.43-3.47-2.75-2.94-2.71-1.95-4.22-1.83-25.67
Earnings per share, diluted-2.43-3.47-2.75-2.94-2.71-1.95-4.22

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents45.4M71.2M63.2M33.7M51.7M50.9M85.8M60.9M4.25M
Short-term investments145.5M284.5M431.0M297.5M148.9M226.0M17.0M0
Receivables823.0K2.30M01.98M2.00M9.28M7.05M500.0K250.0K
Inventory11
Current assets196.4M362.3M505.5M340.3M209.4M290.8M111.9M61.7M4.71M
Property, plant and equipment2.94M5.53M3.57M4.49M4.61M4.32M4.08M4.26M1.85M
Total assets225.2M396.9M512.2M350.6M221.2M295.5M119.1M66.5M6.55M
Accounts payable480.0K5.96M4.53M1.58M2.97M2.02M1.25M2.58M1.59M
Current liabilities16.4M33.2M28.5M23.9M16.8M11.6M8.17M5.08M3.19M
Long-term debt30.2M10.1M9.93M
Total debt030.2M10.1M9.93M0283.0K444.0K525.0K
Total liabilities44.0M92.9M38.6M37.3M22.2M12.5M9.08M67.4M3.19M
Shareholders' equity181.2M304.1M473.6M313.3M199.1M283.1M-76.3M-882.0K3.35M
Shares outstanding61.4M60.9M59.9M48.9M36.1M35.6M1.85M16.5M803.5K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-128.3M-155.5M-116.4M-94.6M-75.4M-37.3M-2.75M-28.3M-16.9M
Capital spending-374.0K-3.85M-921.0K-1.76M-1.95M-1.53M-964.0K-2.32M-1.41M
Free cash flow-128.7M-159.4M-117.3M-96.4M-77.4M-38.8M-3.71M-30.7M-18.3M
Cash from investing134.3M140.3M-127.0M-150.2M73.7M-210.9M-17.9M-2.32M-1.41M
Cash from financing-31.7M23.1M274.4M226.9M2.53M213.2M45.5M87.3M20.0M
Share buybacks215.6M2.53M213.2M48.1M87.3M-12.0K
Change in cash-25.7M7.95M31.0M-18.0M783.0K-34.9M24.9M56.7M1.68M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 2, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
8-K · Current reportAug 11, 2026ResultsSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
3 · Initial statement of ownershipJul 13, 2026Insider tradeSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
3 · Initial statement of ownershipJul 13, 2026Insider tradeSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
8-K · Current reportJul 13, 2026Management or board changeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
8-K · Current reportJun 11, 2026Meeting outcomeSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026ResultsSEC
ARS · Annual report to shareholdersApr 22, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 22, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 22, 2026Meeting noticeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
4 · Change in ownershipApr 17, 2026Insider tradeSEC
8-K · Current reportApr 17, 2026Management or board changeSEC
EFFECT · Notice that a registration is effectiveApr 7, 2026Other filingsSEC
CORRESP · Letter to the SECApr 2, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 2, 2026Other filingsSEC
S-3 · Registration statementMar 30, 2026Offer documentSEC
8-K · Current reportMar 30, 2026Current reportSEC
S-8 · Registration statement for employee plansMar 11, 2026Offer documentSEC
8-K · Current reportMar 11, 2026ResultsSEC
10-K · Annual reportMar 11, 2026Annual reportSEC
8-K · Current reportMar 3, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 9, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 30, 2026Big-stake noticeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 22, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 8, 2026Big-stake noticeSEC
3 · Initial statement of ownershipDec 22, 2025Insider tradeSEC
8-K · Current reportDec 16, 2025Management or board changeSEC
8-K · Current reportDec 8, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
8-K · Current reportOct 24, 2025Management or board changeSEC
8-K · Current reportOct 20, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeSep 4, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 17, 2025Big-stake noticeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
8-K · Current reportJun 9, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
8-K · Current reportMay 1, 2025Management or board changeSEC
DEFA14A · Additional proxy materialApr 23, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2025Meeting noticeSEC
PRER14AApr 11, 2025Other filingsSEC
PRE 14A · Preliminary proxy statementApr 10, 2025Meeting noticeSEC
8-K · Current reportMar 13, 2025Material contractSEC
8-A12B · Registration of shares for listing on an exchangeMar 13, 2025Other filingsSEC
SCHEDULE 13D · Big-stake noticeMar 10, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 7, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 3, 2025Offer documentSEC
10-K · Annual reportMar 3, 2025Annual reportSEC
8-K · Current reportMar 3, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
8-K · Current reportFeb 13, 2025Current reportSEC
8-K · Current reportFeb 10, 2025Current reportSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 22, 2025Insider tradeSEC
4 · Change in ownershipJan 22, 2025Insider tradeSEC
4 · Change in ownershipJan 22, 2025Insider tradeSEC
4 · Change in ownershipJan 22, 2025Insider tradeSEC
4 · Change in ownershipJan 22, 2025Insider tradeSEC
4 · Change in ownershipJan 22, 2025Insider tradeSEC
144 · Notice of proposed saleJan 22, 2025Other filingsSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13G · Big-stake noticeOct 4, 2024Big-stake noticeSEC
8-K · Current reportSep 27, 2024Current reportSEC
10-Q · Quarterly reportAug 7, 2024Quarterly reportSEC
8-K · Current reportAug 7, 2024ResultsSEC
8-K · Current reportJul 15, 2024Current reportSEC
4 · Change in ownershipJul 12, 2024Insider tradeSEC
4 · Change in ownershipJul 12, 2024Insider tradeSEC
4 · Change in ownershipJul 12, 2024Insider tradeSEC
4 · Change in ownershipJul 12, 2024Insider tradeSEC
4 · Change in ownershipJul 12, 2024Insider tradeSEC
4 · Change in ownershipJul 11, 2024Insider tradeSEC
4 · Change in ownershipJul 11, 2024Insider tradeSEC
4 · Change in ownershipJul 11, 2024Insider tradeSEC
4 · Change in ownershipJul 11, 2024Insider tradeSEC
4 · Change in ownershipJul 11, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 17, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Management or board changeSEC
8-K · Current reportMay 14, 2024Current reportSEC
10-Q · Quarterly reportMay 6, 2024Quarterly reportSEC
8-K · Current reportMay 6, 2024ResultsSEC
4 · Change in ownershipMay 6, 2024Insider tradeSEC
DEFA14A · Additional proxy materialApr 22, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 22, 2024Meeting noticeSEC
8-K · Current reportMar 12, 2024Material contractSEC
S-8 · Registration statement for employee plansFeb 27, 2024Offer documentSEC
10-K · Annual reportFeb 27, 2024Annual reportSEC
8-K · Current reportFeb 27, 2024ResultsSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 8, 2024Big-stake noticeSEC
8-K · Current reportFeb 5, 2024Current reportSEC
SC 13G · Big-stake noticeJan 25, 2024Big-stake noticeSEC
4 · Change in ownershipJan 24, 2024Insider tradeSEC
4 · Change in ownershipJan 24, 2024Insider tradeSEC
4 · Change in ownershipJan 24, 2024Insider tradeSEC
4 · Change in ownershipJan 24, 2024Insider tradeSEC
4 · Change in ownershipJan 24, 2024Insider tradeSEC
4 · Change in ownershipJan 24, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
8-K · Current reportOct 3, 2023Material contractSEC
8-K · Current reportSep 26, 2023Current reportSEC
10-Q · Quarterly reportAug 9, 2023Quarterly reportSEC
8-K · Current reportAug 9, 2023ResultsSEC
4 · Change in ownershipAug 7, 2023Insider tradeSEC
144 · Notice of proposed saleAug 3, 2023Other filingsSEC
4 · Change in ownershipJul 21, 2023Insider tradeSEC
144 · Notice of proposed saleJul 20, 2023Other filingsSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
4 · Change in ownershipJul 18, 2023Insider tradeSEC
4 · Change in ownershipJun 14, 2023Insider tradeSEC
4 · Change in ownershipJun 12, 2023Insider tradeSEC
4 · Change in ownershipJun 8, 2023Insider tradeSEC

This page holds 200 of 440 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Pliant Therapeutics, Inc.’s releases · as of Nov 9, 2026

Common shares
61,990,635
Fully diluted
61,990,635

Fully diluted

LineSharesAs of
Common shares61,990,635Nov 9, 2026

Share count over time

CountShares
Nov 9, 202661,990,635

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Tang Capital Management LLC6.14M9.9%US$6.63MSep 30, 2026
ADAR1 Capital Management, LLC5.51M8.9%US$5.95MSep 30, 2026
Vanguard2.97M4.8%US$3.21MSep 30, 2026
Acadian Asset Management LLC2.42M3.9%US$2.6MSep 30, 2026
Two Sigma2.25M3.6%US$2.43MSep 30, 2026
Renaissance Technologies2.05M3.3%US$2.22MSep 30, 2026
Monaco Asset Management SAM2.01M3.2%US$2.17MSep 30, 2026
Lynx1 Capital Management LP1.8M2.9%US$1.94MSep 30, 2026
Woodline Partners LP1.63M2.6%US$1.76MSep 30, 2026
Prosight Management, LP1.6M2.6%US$1.73MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
BML Capital Management, LLC1.55M2.5%US$1.67MSep 30, 2026
Peapod Lane Capital LLC1.21M2.0%US$1.31MSep 30, 2026
BlackRock1.15M1.9%US$1.25MSep 30, 2026
Ikarian Capital, LLC1M1.6%US$1.08MSep 30, 2026
Eversept Partners, LP888K1.4%US$959KSep 30, 2026
Marshall Wace, LLP835K1.3%US$902KSep 30, 2026
Redmile Group, LLC772K1.2%US$834KSep 30, 2026
Geode Capital707K1.1%US$764KSep 30, 2026
Jacobs Levy Equity Management, Inc653K1.1%US$705KSep 30, 2026
Bridgeway Capital Management, LLC552K0.89%US$596KSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.536K0.86%US$579KSep 30, 2026
Bessemer Group Inc527K0.85%US$569KSep 30, 2026
DAFNA Capital Management LLC487K0.79%US$526KSep 30, 2026
Stonepine Capital Management, LLC415K0.67%US$448KSep 30, 2026
Laurion Capital Management LP413K0.67%US$446KSep 30, 2026
Aldebaran Capital, LLC403K0.65%US$436KSep 30, 2026
Torno Capital, LLC400K0.65%US$432KSep 30, 2026
Armistice Capital, LLC336K0.54%US$363KSep 30, 2026
Citadel320K0.52%US$345KSep 30, 2026
Verdad Advisers, LP308K0.50%US$333KSep 30, 2026
XTX Topco Ltd304K0.49%US$328KSep 30, 2026
Boothbay Fund Management, LLC303K0.49%US$327KSep 30, 2026
Nano Cap New Millennium Growth Fund L P300K0.48%US$324KSep 30, 2026
Sei Investments Co297K0.48%US$321KSep 30, 2026
ArrowMark Colorado Holdings LLC281K0.45%US$304KSep 30, 2026
State Street253K0.41%US$274KSep 30, 2026
Gsa Capital Partners LLP248K0.40%US$268KSep 30, 2026
Rangeley Capital, LLC225K0.36%US$243KSep 30, 2026
Jane Street195K0.31%US$210KSep 30, 2026
Goldman Sachs194K0.31%US$210KSep 30, 2026
HighMark Wealth Management LLC166K0.27%US$180KSep 30, 2026
Morgan Stanley147K0.24%US$159KSep 30, 2026
Northern Trust125K0.20%US$135KSep 30, 2026
Algert Global LLC124K0.20%US$134KSep 30, 2026
Osaic Holdings, Inc.115K0.18%US$124KSep 30, 2026
JPMorgan108K0.17%US$116KSep 30, 2026
UBS102K0.16%US$110KSep 30, 2026
Bond & Devick Financial Network, Inc.100K0.16%US$108KSep 30, 2026
Hrt Financial LP93,5230.15%US$101KSep 30, 2026
Dimensional89,8770.14%US$97,068Sep 30, 2026

This page holds 50 of 81 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.75M2.8%US$1.99MJun 30, 2026
Vanguard Extended Market Index Fund616K0.99%US$702KJun 30, 2026
Ultra-Small Company Fund471K0.76%US$537KJun 30, 2026
iShares Micro-Cap ETF207K0.33%US$236KJun 30, 2026
Vanguard Health Care Index Fund153K0.25%US$193KMay 31, 2026
Fidelity Extended Market Index Fund121K0.19%US$152KMay 31, 2026
Invesco RAFI US 1500 Small-Mid ETF104K0.17%US$108KJul 31, 2026
Goldman Sachs Absolute Return Tracker Fund96,0720.15%US$110KJun 30, 2026
Fidelity Total Market Index Fund94,7520.15%US$119KMay 31, 2026
Ultra-Small Company Market Fund82,3000.13%US$93,822Jun 30, 2026
All 26 holders
HolderSharesOf the companyValueAs of
Fidelity Series Total Market Index Fund79,9120.13%US$101KMay 31, 2026
Multi-Manager Small Cap Equity Strategies Fund55,1290.09%US$69,463May 31, 2026
NVIT Small Cap Value Fund50,3000.08%US$57,342Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund46,1930.07%US$52,660Jun 30, 2026
Vanguard Balanced Index Fund31,8890.05%US$36,353Jun 30, 2026
Fidelity Nasdaq Composite Index Fund27,3660.04%US$34,481May 31, 2026
Small Cap Equity Fund22,4880.04%US$25,636Jun 30, 2026
Tiff Multi-Asset Fund17,4290.03%US$19,869Jun 30, 2026
1290 VT Micro Cap Portfolio13,8460.02%US$15,784Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund13,6000.02%US$15,504Jun 30, 2026
JNL/DFA U.S. Small Cap Fund9,5350.02%US$10,870Jun 30, 2026
AST Small-Cap Equity Portfolio7,4000.01%US$8,436Jun 30, 2026
AZL DFA U.S. Core Equity Fund2,307<0.01%US$2,630Jun 30, 2026
LVIP Dimensional U.S. Core Equity 1 Fund1,349<0.01%US$1,538Jun 30, 2026
LVIP Dimensional U.S. Core Equity 2 Fund1,160<0.01%US$1,322Jun 30, 2026
Knights of Columbus U.S. ALL CAP INDEX FUND330<0.01%US$343Jul 31, 2026

Big stakes

StakeStakeSharesDateFiling
Tang Capital Management LLC9.60%5.86MMar 3, 2025Schedule 13D
ADAR1 Capital Management, LLC8.90%5.51MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Suzanne L. Bruhn
Other companies: Definium Therapeutics, Inc. (Director · Since at least Aug 11, 2022); Vigil Neuroscience Inc (Director · Since at least Jul 27, 2022); Travere Therapeutics, Inc. (Director · Since at least Apr 8, 2020); Avalo Therapeutics, Inc. (Director · Apr 24, 2020 – Nov 10, 2021 · Past); Novelion Therapeutics Inc (Director · Oct 1, 2017 – Aug 9, 2018 · Past); Spyre Therapeutics, Inc. (Director · Feb 15, 2017 – Jun 8, 2020 · Past); Raptor Pharmaceutical Corp (Director · Sep 25, 2012 – Oct 24, 2016 · Past)
Director · Since at least Jun 2, 2020
Charles Homcy
Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); BridgeBio Pharma, Inc. (Director · Since at least Jun 27, 2019); Population Health Investment Co Inc (Director · Nov 17, 2020 – Jan 26, 2021 · Past); Portola Pharmaceuticals Inc (Director · Jun 8, 2018 – Jan 2, 2019 · Past); Global Blood Therapeutics Inc (Director · Oct 3, 2017 – Jun 20, 2018 · Past)
Director · Jun 2, 2020 – Jun 29, 2021 · Past
David Pyott
Other companies: Tarsus Pharmaceuticals, Inc. (Director · Since at least Feb 18, 2026); Alnylam Pharmaceuticals, Inc. (Chair · Since at least Dec 18, 2015); BioMarin Pharmaceutical Inc. (Director · Jan 4, 2016 – May 21, 2024 · Past); Edwards Lifesciences Corporation (Director · May 12, 2006 – May 9, 2014 · Past); Avery Dennison Corporation (Director · Mar 31, 2006 – Apr 23, 2020 · Past)
Director · Since at least Jan 12, 2021
Neil Exter
Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Decibel Therapeutics Inc (Director · Feb 11, 2021 – Jun 17, 2022 · Past); Revolution Medicines, Inc. (Director · Feb 12, 2020 – Jun 16, 2022 · Past); Rhythm Pharmaceuticals, Inc. (Director · Oct 4, 2017 – Jun 6, 2018 · Past); CytomX Therapeutics, Inc. (Director · Oct 7, 2015 – Jun 20, 2017 · Past)
Director · Jun 2, 2020 – Jun 16, 2022 · Past
Robert Iannone
Other companies: Autolus Therapeutics plc (Chair of the Research & Development Committee · Since at least Mar 18, 2026); Jazz Pharmaceuticals plc (EVP, Global Head of R&D & CMO · Since at least May 29, 2019); Iteos Therapeutics Inc (Director · Apr 29, 2021 – Jun 11, 2024 · Past); Jounce Therapeutics Inc (Director · Jan 21, 2020 – May 3, 2023 · Past); Immunomedics Inc (CHIEF MEDICAL OFFICER · Apr 12, 2018 – Mar 14, 2019 · Past)
Director · Since at least Jul 9, 2026
Gayle Crowell
Other companies: Hercules Capital, Inc. (Director · Since at least Feb 4, 2019); Envestnet Inc (Director · Mar 29, 2016 – Nov 25, 2024 · Past); Yodlee Inc (Director · Oct 2, 2014 – Nov 19, 2015 · Past); Scientific Learning Corporation (Director · Nov 2, 2010 – May 20, 2012 · Past)
Board Member · Since at least Jun 2, 2020
Katharine Knobil
Other companies: Korro Bio, Inc. (Director · Since at least Aug 26, 2024); Marker Therapeutics, Inc. (Chief Medical Officer, Altesa BioSciences, Inc. · Since at least Dec 8, 2021); Arena Pharmaceuticals Inc (Director · Jun 12, 2020 – Mar 11, 2022 · Past); Kaleido Biosciences, Inc. (Chief Medical Officer · Feb 27, 2019 – Oct 15, 2020 · Past)
Director · Since at least Sep 14, 2022
Steve Krognes
Other companies: argenx SE (Non-executive director, Chairperson of the Audit and Compliance Committee, Member of the Remuneration & Nomination Committee · Since at least Nov 6, 2026); Denali Therapeutics Inc. (Director · Since at least Jul 19, 2022); Guardant Health, Inc. (Director · Since at least Jun 30, 2022); Gritstone bio, Inc. (Director · Jun 17, 2022 – Jun 16, 2023 · Past)
Director · Since at least Jun 13, 2024
Darren Cline
Other companies: Xenon Pharmaceuticals Inc. (Chief Commercial Officer · Since at least Jun 23, 2025); Pyxis Oncology, Inc. (Director · Since at least Mar 26, 2024)
Board Member · Since at least Jun 13, 2024
Flavia Borellini
Other companies: Revolution Medicines, Inc. (Director · Since at least Jun 22, 2021); Viracta Therapeutics Inc (Director · Aug 14, 2021 – Jun 20, 2024 · Past)
Director · Since at least Jul 9, 2026
All 26 people
PersonSeat
Smital Shah
Other companies: Lyell Immunopharma, Inc. (Chief Financial and Business Officer · Since at least Mar 9, 2026); LENZ Therapeutics, Inc. (Director · Apr 15, 2021 – Jul 19, 2023 · Past)
Director · Jun 2, 2020 – Jun 13, 2024 · Past
Bernard Coulie
Other companies: Septerna, Inc. (Director · Since at least Oct 24, 2024)
Director · Since at least Jun 2, 2020
Hans Hull
Other companies: Adverum Biotechnologies Inc (Chief Executive Officer · Jul 30, 2014 – Aug 21, 2015 · Past)
Chief Business Officer · Jun 2, 2020 – Jan 23, 2025 · Past
Hoyoung Huh
Other companies: Akari Therapeutics PLC (Chairman · Since at least Nov 14, 2024)
Director · Since at least Jun 16, 2022
Thomas McCourt
Other companies: Ironwood Pharmaceuticals, Inc. (Chief Executive Officer, Director · Since at least May 23, 2022)
Director · Since at least Mar 6, 2023
Barbara HowesChief Human Resource Officer · Jun 2, 2020 – Jan 23, 2021 · Past
Craig BlanchetteSenior Vice President, Research · Since at least Oct 20, 2026
David RabenChief Medical Officer · Since at least Sep 30, 2026
Eric LefebvreChief Medical Officer · Jun 2, 2020 – Jan 23, 2025 · Past
John CurnutteDirector · Since at least Jun 5, 2025
Katerina LeftherisDirector · Jan 9, 2026 – Nov 5, 2026 · Past
Keith Lamont CummingsChief Financial Officer · Since at least Jan 17, 2024
Lily CheungChief Human Resource Officer · Since at least Jan 23, 2024
Mike OuimetteGeneral Counsel & Corp. Sec'y · Oct 1, 2020 – Jan 23, 2025 · Past
Minnie KuoChief Operating Officer · Since at least Dec 10, 2025
Steve KrognesMember · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Pliant Therapeutics, Inc.